Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab plus chemotherapy and bevacizumab for advanced melanoma
ChiCTR2500103154Phase 2Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- May 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel, carboplatin and bevacizumab in melanoma, sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcarboplatinbevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2500103154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103154.